On Thursday, September 8, before market open, Descartes will report its Q2, 2017 results. Abernethy expects the company will generate EBITDA of $16.7-million on revenue of $50.1-million, numbers that are in-line with the street consensus of EBITDA of $16.9-million on revenue of $50.5-million.
Abernethy says Descartes is now a story of simultaneous headwinds and tailwinds.
“We will be keying in on signs of traction in the retail vertical, performance in recently acquired businesses (such as MK Data), and regulatory tailwinds,” he says. “However, from a macro perspective, we note that US rail and freight indexes have been somewhat weaker this year, which could impact some of Descartes’ transaction volumes. Key catalysts for the stock this year include materially accretive acquisitions, a more rapid pace of large retailer project wins, and an uptick in organic network revenue growth.
Abernethy thinks Descartes will generate EBITDA of $67.7-million on revenue of $202.6-million in fiscal 2017, numbers he expects will grow to EBITDA of $74.1-million on revenue of $216.5-million the following year.
In a research update to clients today, Abernethy maintained his “Hold” rating and one-year price target of $21.00 on Descartes Systems Group, implying a return of 1.2 per cent at the time of publication.
Roth Capital Markets analyst Richard Baldry maintained a “Buy” rating and US$395.00 price target on Salesforce (Salesforce Stock Quote, Chart, News,… [Read More]
Canada shed 66,000 jobs in August, marking a second straight monthly contraction and pushing the unemployment rate up to 7.1%,… [Read More]
Rebecca Teltscher, Portfolio Manager at Newhaven Asset Management, told BNN Bloomberg’s Market Watch on Sept. 3 that she sees long-term… [Read More]
Barry Schwartz, president and chief investment officer at Baskin Wealth Management, told BNN Bloomberg’s Market Watch on Sept. 2 that… [Read More]
Roth Capital Markets analyst Rohit Kulkarni maintained a “Buy” rating and US$210.00 target price on Alphabet (Alphabet Stock Quote, Chart,… [Read More]
Paradigm Capital analyst Scott McAuley maintained a “Speculative Buy” rating but lowered his target price for Perimeter Medical Imaging AI… [Read More]